Gregory A. Demopulos
Net Worth
Last updated:
What is Gregory A. Demopulos net worth?
The estimated net worth of Dr. Gregory A. Demopulos is at least $33,382,747 as of 17 Nov 2023. He owns shares worth $541,640 as insider, has earned $1,481,107 from insider trading and has received compensation worth at least $31,360,000 in Omeros Corporation.
What is the salary of Gregory A. Demopulos?
Dr. Gregory A. Demopulos salary is $2,240,000 per year as Co-Founder, Chairman, Chief Executive Officer & Pres in Omeros Corporation.
How old is Gregory A. Demopulos?
Dr. Gregory A. Demopulos is 66 years old, born in 1959.
What stocks does Gregory A. Demopulos currently own?
As insider, Dr. Gregory A. Demopulos owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Omeros Corporation (OMER) | Co-Founder, Chairman, Chief Executive Officer & Pres | 123,945 | $4.37 | $541,640 |
What does Omeros Corporation do?
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Gregory A. Demopulos insider trading
Omeros Corporation
Dr. Gregory A. Demopulos has made 12 insider trades between 2011-2023, according to the Form 4 filled with the SEC. Most recently he purchased 15,000 units of OMER stock worth $25,200 on 17 Nov 2023.
The largest trade he's ever made was exercising 283,203 units of OMER stock on 2 Dec 2016. As of 17 Nov 2023 he still owns at least 123,945 units of OMER stock.
Omeros key executives
Omeros Corporation executives and other stock owners filed with the SEC:
- Dr. Gregory A. Demopulos (66) Co-Founder, Chairman, Chief Executive Officer & Pres
- Mr. Michael A. Jacobsen (67) Chief Accounting Officer, Vice President of Fin. & Treasurer
- Mr. Peter B. Cancelmo J.D. (46) Vice President, Gen. Counsel & Corporation Sec.